|
The European Generic medicines Association (EGA) is the association and the official representative body of the European Generic and Biosimilar pharmaceutical industry, which is at the forefront of providing high-quality affordable Medicines to millions of Europeans and stimulating competitiveness and innovation in the pharmaceutical sector. The association’s headquarters are located in at the Brussels Maison Européenne de la Protection Sociale, which is a two-minute walk from the European Parliament. The EGA has subscribed to the Transparency Register〔()〕 set up and operated by the European Parliament and the European Commission.〔(Joint EGA & GPHA Response to the EU-US High Level Working Group on Jobs & Growth on Regulatory Issues )〕 ==Purpose and objectives== The objectives of the Association are, without any profit purpose, to represent, support and develop the common scientific and technical interests of the generic pharmaceutical industry and the biosimilar industry or national or European associations of such, firms, companies or other legal bodies active in the generic pharmaceutical or the biosimilar industries.〔(Generic medicines in the European Union )〕 Those interests shall include, but shall not be restricted to, developments within the European Union, Europe as a whole and relations between the European Union and third countries.〔(Purpose and objectives )〕〔(Criteria for membership )〕〔(EGA's Vision 2015 )〕 For avoidance of doubt, the objectives shall include, but shall not be limited to: *to monitor, study and analyse scientific and technical subjects of common interest to the members *to encourage the formation of generic pharmaceutical and biosimilar associations in countries where they do not yet exist *to inform the members of all trends and developments of common interest to the members *to develop, co-ordinate and implement common positions of the members *to support any European or international authority in respect of issues of common interest and, where necessary, to make representations to such authorities *to inform, when necessary, the general public of issues of common interest to the members *to foster and maintain contacts with European associations and institutions representing interests relevant to the generics and biosimilar industries *to co-operate with national associations of generic and biosimilar producers *to maintain relations with professional organisations concerned with health *and lastly, through its general activities, to seek to promote progress in the generic pharmaceutical and biosimilar industries by quality improvements in products 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「European Generic Medicines Association」の詳細全文を読む スポンサード リンク
|